GSK and Theravance Announce Results of Two Pivotal Phase III Studies for Relovair(TM) in COPD
GlaxoSmithKline (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the results of two pivotal 6-month efficacy and safety phase III studies of Relovair for patients with chronic obstructive pulmonary disease. Results of both studies support the continuation of the Relovair development programme in the COPD patient population.
Relovair is a once-daily inhaled corticosteroid /long-acting beta-agonist combination treatment, comprising fluticasone furoate and vilanterol (FF/VI), currently under development for the treatment of COPD and asthma.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.